Cougars and Pumas and Cash, Oh my!

After he orchestrated the development and sale of Zytiga to J&J (for $1B), has Alan Auerbach struck gold again after Puma's successful phase III testing for the HER-2 positive breast cancer therapy, the rights to which he secured from Pfizer?

http://www.bloomberg.com/news/2014-07-22/puma-biotechnology-soars-on-breast-cancer-drug-results.html

http://www.fiercebiotech.com/story/cougar-founder-snags-pfizer-cancer-drug-raises-55m-and-launches-new-biotech/2011-10-06

 

Synergy or Scandal?

Will the end result of AbbVie's $54 billion dollar purchase of Shire be portfolio synergy or simply tax inversion scandal?



http://www.thestreet.com/story/12778544/1/how-will-abbvie-abbv-stock-react-to-merger-with-shire-pharmaceuticals-shpg.html

Bridging Biology and Business - LinkedIn Group

If you like the content found on this blog, please take a moment to follow the content on my LinkedIn group page as well!

Bridging Biology and Business